InterCure 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Alex Rabinovich

최고 경영자

₪1.4m

총 보상

CEO 급여 비율	51.5%
CEO 임기	5.8yrs
CEO 소유권	26.6%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6.2yrs

최근 관리 업데이트

Recent updates

InterCure Chairman Ehud Barak, CEO Alex Rabinovitch - Israel Cannabis And Beyond (Video)

Nov 08

InterCure: Internationally Profitable Cannabis (Podcast Transcript)

Sep 19

InterCure: Ignored Uplisting

Sep 09

CEO 보상 분석

Alex Rabinovich 의 보수는 InterCure 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-₪66m
Mar 31 2024	n/a	n/a	-₪61m
Dec 31 2023	₪1m	₪728k	-₪62m
Sep 30 2023	n/a	n/a	-₪20m
Jun 30 2023	n/a	n/a	₪21m
Mar 31 2023	n/a	n/a	₪32m
Dec 31 2022	₪1m	₪500k	₪45m
Sep 30 2022	n/a	n/a	₪33m
Jun 30 2022	n/a	n/a	₪24m
Mar 31 2022	n/a	n/a	₪15m
Dec 31 2021	₪180k	₪180k	₪5m
Sep 30 2021	n/a	n/a	₪17m
Jun 30 2021	n/a	n/a	₪20m
Mar 31 2021	n/a	n/a	₪13m
Dec 31 2020	₪122k	₪122k	-₪37m

보상 대 시장: Alex 의 총 보상 ($USD 381.51K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 650.80K ).

보상과 수익: 회사가 수익성이 없는 동안 Alex 의 보상이 증가했습니다.

CEO

Alex Rabinovich (53 yo)

5.8yrs

테뉴어

₪1,414,000

보상

Mr. Alexander Rabinovich, also known as Alex, is Chief Executive Officer and Director of InterCure Ltd. since January 1, 2019 and October 2018 respectively. Mr. Rabinovich is Chief Executive Officer and Di...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Alexander Rabinovich	CEO & Director	6.1yrs	₪1.41m	26.58% $ 16.4m
Ehud Barak	Chairman of the Board	6.2yrs	₪445.00k	2.25% $ 1.4m
Alon Granot	Non-Executive Director	4yrs	₪152.00k	데이터 없음
David Salton	Independent Director	9.9yrs	₪201.00k	0.0088% $ 5.5k
Lennie Grinbaum	Independent External Director	9.2yrs	₪201.00k	0.024% $ 14.6k
Gideon Hirschfeld	Independent External Director	6.2yrs	₪201.00k	0.0088% $ 5.5k

6.2yrs

평균 재임 기간

60.5yo

평균 연령

경험이 풍부한 이사회: INCR 의 이사회는 경험(평균 재직 기간 6.2 년)으로 간주됩니다.

InterCure 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

InterCure Ltd. Announces Resignation of Rami Levy as Chief of Operations

InterCure Ltd., Annual General Meeting, Dec 14, 2023

InterCure Ltd., Annual General Meeting, Sep 15, 2022

Insider recently sold US$427k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Recent updates

InterCure: A Cannabis Industry Leader Still Flying Under The Radar

InterCure Ltd. announced delayed 20-F filing

InterCure: Bargain Israel Cannabis Play

InterCure Ltd. Announces Resignation of Rami Levy as Chief of Operations

InterCure Ltd., Annual General Meeting, Dec 14, 2023

InterCure Ltd. Wins Cannolam Arbitration Proceeding

InterCure Announces Proposed Voluntary Delisting from the Toronto Stock Exchange

InterCure Announces Proposed Voluntary Delisting from the Toronto Stock Exchange

Better Files A Lawsuit Against InterCure and its Chairman Ehud Barak

Investor sentiment improves as stock rises 16%

Price target decreased by 50% to US$5.00

First quarter 2023 earnings released: EPS: ₪0.005 (vs ₪0.38 in 1Q 2022)

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorated over the past week

InterCure Ltd. Announces the Withdrawal of Class Action Lawsuit Against It

InterCure Ltd. (TASE:INCR) entered into an agreement to acquire 51% stake in Orni Pharmacy Ltd.

Intercure Provides Revenue Guidance for Fourth Quarter 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

InterCure: A Leader In Global Cannabis

Second quarter 2022 earnings: EPS misses analyst expectations

InterCure reports Q2 results

InterCure Ltd. to Report Q2, 2022 Results on Aug 15, 2022

InterCure Ltd. Announces Revenue Guidance for the Second Quarter of 2022

InterCure Ltd., Annual General Meeting, Sep 15, 2022

InterCure Is Growing In The Massive Global Cannabis Market

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

InterCure Ltd. Provides Revenue Guidance for the Second Quarter and Full Year of 2022

InterCure Ltd. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Now 23% undervalued

Intercure Ltd. Provides Revenue Results Fourth Quarter and Fiscal Year 2021

InterCure Ltd. to Report Q4, 2021 Results on Mar 31, 2022

Insider recently sold US$427k worth of stock

Investor sentiment improved over the past week

Less than half of directors are independent

IntureCure: Israel Recreation Cannabis Boom On The Way

Investor sentiment improved over the past week

Intercure Ltd. Provides Preliminary Earnings Guidance for the Fourth Quarter and Fiscal Year 2021 and Fiscal Year 2022

Third quarter 2021 earnings released: ₪0.04 loss per share (vs ₪0.067 profit in 3Q 2020)

Investor sentiment improved over the past week

InterCure Chairman Ehud Barak, CEO Alex Rabinovitch - Israel Cannabis And Beyond (Video)

InterCure: Internationally Profitable Cannabis (Podcast Transcript)

Price target increased to US$10.00

Less than half of directors are independent

Price target increased to US$10.00

Less than half of directors are independent

InterCure: Ignored Uplisting

Price target increased to US$10.00

Less than half of directors are independent

Price target increased to US$10.00

Less than half of directors are independent

InterCure Ltd. (TASE:INCR) entered into an agreement to acquire Max Pharm/Hello Pharm/A Pharmacy from Cannomed Medical Cannabis Industries LTD (TASE:CNMD).

Less than half of directors are independent

Price target increased to US$10.00

Investor sentiment improved over the past week

InterCure Ltd. (TASE:INCR) agreed to acquire better of Cann Pharmaceutical Ltd.

InterCure Ltd (TASE:INCR) signed a definitive agreement to acquire Licensed active medical cannabis trading house and two pharmacies located in Israel.

InterCure Ltd Provides Earnings Guidance for the First Quarter of 2021; Provides Revenue Guidance for the Second Quarter and Full Year 2021

InterCure Ltd Announces Executive Changes

Charlotte's Web, Inc. Signs Exclusive Distribution Agreement in Israel with InterCure Ltd and Canndoc Ltd

InterCure Ltd. (TASE:INCR) completed the acquisition of additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments (1996) Ltd.

CEO 보상 분석

CEO

테뉴어

보상